130 related articles for article (PubMed ID: 12969965)
1. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
Kishi S; Yang W; Boureau B; Morand S; Das S; Chen P; Cook EH; Rosner GL; Schuetz E; Pui CH; Relling MV
Blood; 2004 Jan; 103(1):67-72. PubMed ID: 12969965
[TBL] [Abstract][Full Text] [Related]
2. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia.
van de Poll ME; Relling MV; Schuetz EG; Harrison PL; Hughes W; Flynn PM
Cancer Chemother Pharmacol; 2001 Jun; 47(6):467-72. PubMed ID: 11459198
[TBL] [Abstract][Full Text] [Related]
3. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.
Anderer G; Schrappe M; Brechlin AM; Lauten M; Muti P; Welte K; Stanulla M
Pharmacogenetics; 2000 Nov; 10(8):715-26. PubMed ID: 11186134
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
Blanco JG; Edick MJ; Hancock ML; Winick NJ; Dervieux T; Amylon MD; Bash RO; Behm FG; Camitta BM; Pui CH; Raimondi SC; Relling MV
Pharmacogenetics; 2002 Nov; 12(8):605-11. PubMed ID: 12439220
[TBL] [Abstract][Full Text] [Related]
6. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
[TBL] [Abstract][Full Text] [Related]
7. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.
Yates CR; Zhang W; Song P; Li S; Gaber AO; Kotb M; Honaker MR; Alloway RR; Meibohm B
J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518
[TBL] [Abstract][Full Text] [Related]
8. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
Kamdem LK; Hamilton L; Cheng C; Liu W; Yang W; Johnson JA; Pui CH; Relling MV
Pharmacogenet Genomics; 2008 Jun; 18(6):507-14. PubMed ID: 18496130
[TBL] [Abstract][Full Text] [Related]
9. [Increased frequency of A-G transition at exon 5 of GSTP1 as a genetic risk factor for acute childhood leukaemia].
Zubowska M; Zielińska E; Zmysłowska A; Bodalski J
Med Wieku Rozwoj; 2004; 8(2 Pt 1):245-57. PubMed ID: 15738600
[TBL] [Abstract][Full Text] [Related]
10. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
11. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia.
Krajinovic M; Labuda D; Sinnett D
Pharmacogenetics; 2002 Nov; 12(8):655-8. PubMed ID: 12439226
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.
Katz DA; Grimm DR; Cassar SC; Gentile MC; Ye X; Rieser MJ; Gordon EF; Polzin JE; Gustavson LE; Driscoll RM; O'dea RF; Williams LA; Bukofzer S
Clin Pharmacol Ther; 2004 Jun; 75(6):516-28. PubMed ID: 15179406
[TBL] [Abstract][Full Text] [Related]
13. Glutathione S-transferase P1 genotypes, genetic susceptibility and outcome of therapy in thai childhood acute lymphoblastic leukemia.
Gatedee J; Pakakassama S; Muangman S; Pongstaporn W
Asian Pac J Cancer Prev; 2007; 8(2):294-6. PubMed ID: 17696749
[TBL] [Abstract][Full Text] [Related]
14. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
[TBL] [Abstract][Full Text] [Related]
15. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia.
Stanulla M; Schäffeler E; Arens S; Rathmann A; Schrauder A; Welte K; Eichelbaum M; Zanger UM; Schrappe M; Schwab M
Int J Hematol; 2005 Jan; 81(1):39-44. PubMed ID: 15717687
[TBL] [Abstract][Full Text] [Related]
16. GSTM1 and GSTP1 Genetic Polymorphisms and Their Associations With Acute Lymphoblastic Leukemia Susceptibility in a Jordanian Population.
Al-Eitan LN; Rababaʼh DM; Alkhatib RQ; Khasawneh RH; ALjarrah OA
J Pediatr Hematol Oncol; 2016 Oct; 38(7):e223-9. PubMed ID: 27299594
[TBL] [Abstract][Full Text] [Related]
17. [Analysis on GST-Pi genetic polymorphism in children with acute leukemia].
Yuan XJ; Gu LJ; Xue HL; Tang JY; Zhao JC; Chen J; Wang YP; Chen J; Pan C; Song DL
Zhonghua Yi Xue Za Zhi; 2003 Nov; 83(21):1863-6. PubMed ID: 14642067
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
[TBL] [Abstract][Full Text] [Related]
20. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
